SCHEMBL22680195

SCHEMBL22680195

C=C(C)CN(C)C1Cc2cccc3[nH]cc(c23)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.39
KDM4E B2RXH2 5/20 0.38
HSD17B10 Q99714 5/20 0.38
MEN1 O00255 4/20 0.38
CYP3A4 P08684 4/20 0.38
MAPT P10636 4/20 0.38
KMT2A Q03164 4/20 0.38
ALDH1A1 P00352 4/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
HTR7 P34969 2/20 0.38
HTR2B P41595 2/20 0.38
HTR6 P50406 2/20 0.38
CYP1A2 P05177 2/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
APEX1 P27695 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
DRD2 P14416 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30797718 0.80 SLC6A4 (0.46) HTR1AKDM4EHSD17B10MEN1CYP3A4
SCHEMBL9790419 0.80 SLC6A4 (0.46) HTR1AKDM4EHSD17B10MEN1CYP3A4
SCHEMBL29904413 0.75 HTR1A (0.46) HTR1AKDM4EHSD17B10MEN1CYP3A4
SCHEMBL23249538 0.75 HTR1A (0.46) HTR1AKDM4EHSD17B10MEN1CYP3A4
SCHEMBL23248781 0.75 HTR1A (0.46) HTR1AKDM4EHSD17B10MEN1CYP3A4
SCHEMBL23248780 0.75 HTR1A (0.46) HTR1AKDM4EHSD17B10MEN1CYP3A4
SCHEMBL4797051 0.73 DRD3 (0.59) HTR1ADRD2DRD3HTR1D
SCHEMBL23261873 0.72 MEN1 (0.42) KDM4EHSD17B10MEN1CYP3A4MAPT
SCHEMBL26266600 0.72 MEN1 (0.52) KDM4EHSD17B10MEN1CYP3A4MAPT
SCHEMBL3658074 0.68 MEN1 (0.44) HTR1AKDM4EHSD17B10MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020232255-A1 COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS THE SCRIPPS RESEARCH INSTITUTE (US) 2020-11-19 WO disclosed